{"id":4004,"date":"2023-10-09T12:33:22","date_gmt":"2023-10-09T12:33:22","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/"},"modified":"2026-01-22T17:03:31","modified_gmt":"2026-01-22T17:03:31","slug":"evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/","title":{"rendered":"Evaluation of protein biomarkers in brain homogenate and plasma from different animal models of Alzheimer’s Disease: P301S and APP\/PSEN1"},"content":{"rendered":"

Alzheimer\u2019s disease (AD) is a multifactorial disease with unpredictable onset and rate of progression. Consequently, biomarkers that detect and track disease progression are important medically but are also critical from an R&D translational perspective.<\/p>\n

At Sygnature Discovery, we are utilising suitable\u00a0in vivo<\/em>\u00a0models: APP\/PSEN1 and P301S mice, both recognised models of AD and developing platforms that accurately measure biomarkers with translational applicability<\/a>.<\/p>\n

Using Jess Western blot platform (Bio-Techne<\/a>), ELISA, and Meso Scale Discovery S-Plex assay (MSD) platforms, we demonstrate the capability to detect and quantify clinically relevant biomarkers including total Tau (tTau) and phospho-Tau species (pTau-S396 and pTau-T181), Amyloid \u03b2-protein (A\u03b2), A\u03b2 precursor protein (APP), Neurofilament (NFL), and Presenilin 1 (PSEN1) in brain tissue and biofluid.<\/p>\n","protected":false},"excerpt":{"rendered":"

Alzheimer\u2019s disease (AD) is a multifactorial disease with unpredictable onset and rate of progression. To address this, Sygnature Discovery utilizes suitable in vivo models, such as APP\/PSEN1 and P301S mice, recognized models of AD. We are developing platforms that accurately measure clinically relevant biomarkers like total Tau (tTau), phospho-Tau species (pTau-S396 and pTau-T181), Amyloid \u03b2-protein (A\u03b2), A\u03b2 precursor protein (APP), Neurofilament (NFL), and Presenilin 1 (PSEN1) in brain tissue and biofluid. Our approach combines Jess Western blot, ELISA, and Meso Scale Discovery S-Plex assay (MSD) platforms, providing crucial insights for both medical and R&D translational purposes.<\/p>\n","protected":false},"featured_media":2673,"template":"","category":[681,735,740,685,753,688],"class_list":["post-4004","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-bioscience","category-cns-pain-models","category-ex-vivo-tissue-analysis","category-in-vivo-pharmacology","category-neuroscience","category-therapeutic-areas"],"acf":[],"yoast_head":"\nEvaluation of Protein Biomarkers in Brain Homogenate and Plasma<\/title>\n<meta name=\"description\" content=\"Discover how Sygnature Discovery is advancing Alzheimer's disease research with biomarkers and in vivo models.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluation of Protein Biomarkers in Brain Homogenate and Plasma\" \/>\n<meta property=\"og:description\" content=\"Discover how Sygnature Discovery is advancing Alzheimer's disease research with biomarkers and in vivo models.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T17:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Biomarkers_Poster_TR-2_v2-e1744810312390.png\" \/>\n\t<meta property=\"og:image:width\" content=\"628\" \/>\n\t<meta property=\"og:image:height\" content=\"888\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/\",\"name\":\"Evaluation of Protein Biomarkers in Brain Homogenate and Plasma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Biomarkers_Poster_TR-2_v2-e1744810312390.png\",\"datePublished\":\"2023-10-09T12:33:22+00:00\",\"dateModified\":\"2026-01-22T17:03:31+00:00\",\"description\":\"Discover how Sygnature Discovery is advancing Alzheimer's disease research with biomarkers and in vivo models.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Biomarkers_Poster_TR-2_v2-e1744810312390.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Biomarkers_Poster_TR-2_v2-e1744810312390.png\",\"width\":628,\"height\":888},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaluation of protein biomarkers in brain homogenate and plasma from different animal models of Alzheimer’s Disease: P301S and APP\\\/PSEN1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluation of Protein Biomarkers in Brain Homogenate and Plasma","description":"Discover how Sygnature Discovery is advancing Alzheimer's disease research with biomarkers and in vivo models.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/","og_locale":"fr_CA","og_type":"article","og_title":"Evaluation of Protein Biomarkers in Brain Homogenate and Plasma","og_description":"Discover how Sygnature Discovery is advancing Alzheimer's disease research with biomarkers and in vivo models.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/","og_site_name":"Sygnature","article_modified_time":"2026-01-22T17:03:31+00:00","og_image":[{"width":628,"height":888,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Biomarkers_Poster_TR-2_v2-e1744810312390.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/","name":"Evaluation of Protein Biomarkers in Brain Homogenate and Plasma","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Biomarkers_Poster_TR-2_v2-e1744810312390.png","datePublished":"2023-10-09T12:33:22+00:00","dateModified":"2026-01-22T17:03:31+00:00","description":"Discover how Sygnature Discovery is advancing Alzheimer's disease research with biomarkers and in vivo models.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Biomarkers_Poster_TR-2_v2-e1744810312390.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Biomarkers_Poster_TR-2_v2-e1744810312390.png","width":628,"height":888},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/evaluation-of-protein-biomarkers-in-brain-homogenate-and-plasma-from-different-animal-models-of-alzheimers-disease-p301s-and-app-psen1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Evaluation of protein biomarkers in brain homogenate and plasma from different animal models of Alzheimer’s Disease: P301S and APP\/PSEN1"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4004\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2673"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=4004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=4004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}